Soligenix is ready for commercialization of sgx301 (hybryte(tm)); fda has approval process on fast track

New york, new york--(newsfile corp. - february 23, 2021) - pcg digital -- operational efficiency and sound financial management lead to positive results. that statement sums up why soligenix (nasdaq: sngx) is fast approaching a new drug application (nda) submission and potential fda approval for sgx301 (synthetic hypericin), a photodynamic treatment option to battle the debilitating effects of cutaneous t-cell lymphoma (ctcl).the most recent treatment option in their rare disease pipeline, sgx301, will potentially...
SNGX Ratings Summary
SNGX Quant Ranking